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Toxoplasma gondii is a neurotropic protozoan parasite, which is linked to neurological
manifestations in immunocompromised individuals as well as severe neurodevelopmental
sequelae in congenital toxoplasmosis. While the complement system is the first line of host
defense that plays a significant role in the prevention of parasite dissemination,
Toxoplasma artfully evades complement-mediated clearance via recruiting complement
regulatory proteins to their surface. On the other hand, the details of Toxoplasma and the
complement system interaction in the brain parenchyma remain elusive. In this study,
infection-induced changes in the mRNA levels of complement components were analyzed
by quantitative PCR using a murine Toxoplasma infection model in vivo and primary glial
cells in vitro. In addition to the core components C3 and C1q, anaphylatoxin C3a and C5a
receptors (C3aR and C5aR1), as well as alternative complement pathway components
properdin (CFP) and factor B (CFB), were significantly upregulated 2 weeks after
inoculation. Two months post-infection, CFB, C3, C3aR, and C5aR1 expression
remained higher than in controls, while CFP upregulation was transient. Furthermore,
Toxoplasma infection induced significant increase in CFP, CFB, C3, and C5aR1 in mixed
glial culture, which was abrogated when microglial activation was inhibited byorg February 2021 | Volume 11 | Article 6039241
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Frontiers in Immunology | www.frontiersin.pre-treatment with minocycline. This study sheds new light on the roles for the
complement system in the brain parenchyma during Toxoplasma infection, which may
lead to the development of novel therapeutic approaches to Toxoplasma infection-
induced neurological disorders.Keywords: complement, Toxoplasma, cerebral toxoplasmosis, infection, brain, microgliaINTRODUCTION
Toxoplasma gondii is a highly prevalent neurotropic parasite,
infecting over one third of the global population. In healthy
individuals, it is typically asymptomatic or presents with only
mild symptoms such as malaise and fever, which are self-
resolving (1). However, it can cause severe diseases,
particularly in the retina and brain (cerebral toxoplasmosis), in
immunocompromised individuals and children born to mothers
exposed to primary infection during pregnancy (2). Vertical
transmission of Toxoplasma increases the risk of premature
birth and stillbirth (3, 4). In addition, it has a significant
impact on the fetal brain development, resulting in congenital
toxoplasmosis with devastating neurological impairments,
including blindness, retinochoroiditis, seizures, and increased
lifetime risk for mental illnesses, such as schizophrenia, autism,
bipolar disorder, and depression, that may develop later in life (2,
3, 5). Humans and other vertebrates, including rodents, become
infected via oral ingestion of oocysts shed by the definitive host
(felines) or cysts in the tissue of infected animals. After release
into the intestinal epithelium, those parasites transform into fast-
replicating tachyzoites, the tissue-damaging life stage of T.
gondii. Due to the immune surveillance, the tachyzoites may
transform into slow replicating bradyzoites, the cyst-forming
dormant life stage. Cysts are preferentially formed in the brain
and retina (6), leading to chronic infection. Coordinated
responses of innate and acquired immune systems are crucial
in the host defense against Toxoplasma infection. By controlling
the proliferation of tissue-damaging tachyzoites via recruitment
of immune cells and molecules, cytokines, including interleukin
12 (IL-12) and interferon g (IFN-g), play a central role in the
suppression of acute toxoplasmosis (7).
The complement system is the first line of host defense
against infection, and can be initiated via three major
pathways: the classical, lectin, and alternative pathways (8).
Recognition of antigen-antibody complexes activates the
classical pathway, whereas the lectin pathway is initiated upon
mannose-binding lectin (MBL) binding to microbial
carbohydrates. The alternative pathway is constantly and
spontaneously activated by the hydrolysis of C3 and
recognition of foreign surfaces, and is strictly controlled by
regulatory proteins, including positive regulators (factor P, also
called properdin, and factor B) and a negative regulator (factor
H), to prevent potential damage to the host. The recognition
triggers a proteolytic cascade that eventually leads to the
assembly of the terminal complement complex called the
membrane attack complex (MAC), composed of C5b, C6, C7,
C8, and several C9 molecules, which disrupts the membrane oforg 2the target. In addition, the proteolytic cascade generates
anaphylatoxins C3a and C5a, which further enhance innate
and adaptive immunity via their cognate receptors: C3a
receptor (C3aR) and C5a receptors (C5aR1 and C5aR2) (8).
C3aR and C5aR1 are expressed both in the murine and human
brains, whereas it is unknown whether C5aR2 is expressed in the
human brain (9). While the complement system plays an
essential role as the first line of defense as well as a bridge
between innate and adaptive immunity upon infection, excessive
complement activation contributes to a wide range of
inflammatory disorders and damages tissues (10, 11).
Although it was originally thought to be involved in innate
immunity in the blood, complement components, including
C1q, C3, and their receptors are locally produced in the brain
parenchyma (12, 13). Growing evidence suggests diverse roles for
the complement system in the maintenance of neural circuits
during development, aging, and neurological disorders (14, 15).
C1q and C3 are critical mediators of synaptic plasticity during
development (16, 17), while aberrant activation of these factors is
likely involved in neuroinflammation in Alzheimer’s disease
(18). C3a plays crucial roles in the regulation of neurogenesis,
and protects the developing and mature brain against ischemic
injuries (19–21). On the other hand, C5aR1 signaling is
associated with poor outcome after subarachnoid hemorrhage
in human patients as well as in rodent models (22), and C5a-
dependent chemotactic activity is linked to brain damage and
disease severity in bacterial meningitis (23). In experimental
malaria models, in utero exposure-induced cognitive deficits in
the offspring are mediated by C5aR1 signaling (24), suggesting
detrimental consequences of excessive C5aR1 signaling activity
on CNS development. CFB and properdin levels significantly
increased in the brain of scrapie-infected mice (25), and
alternative complement pathway inhibition improved repair
and regeneration after cerebral ischemia and reperfusion injury
(26), suggesting that the alternative pathway is activated in
response to infection and injury, with detrimental
consequences to CNS functionality. Meanwhile, evidence
suggests that glial cells produce complement components upon
stimulation. Astrocytes constitutively produce C3 (27), the
expression of which is enhanced upon stimulation by
inflammatory mediators, such as IFN-g (28). CFB is
synthesized in astrocytes in response to stimulation by LPS
and IFN-g (27, 29). Alternative pathway activation is involved
in microglial priming and overactivation, which may confer
susceptibility to neurodegeneration (30). In addition, C3aR
signaling mediates microglia-astrocyte crosstalk and induces
microglial polarization (31) as well as chemotaxis (32, 33).
Considering the crucial roles for astrocytes and microglia inFebruary 2021 | Volume 11 | Article 603924
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suggest the involvement of glia-dependent complement
activation in brain development and repair processes.
Although there is no doubt that the complement system is
involved in the host defense in the acute phase of Toxoplasma
infection (36–41), it is only recently that the interaction between
Toxoplasma and the complement system in the brain has been
brought to light. Persistent Toxoplasma infection led to the
upregulation of C1q, C1r, C3 and C4 and deposition of
complement component proteins (C1q and C3) in the brain
(42–44), which may be associated with neurodegeneration (43).
However, it is uncertain which pathways are persistently
activated in the brain parenchyma, and what cell types are
responsible for Toxoplasma infection-induced complement
activation. Toxoplasma readily infects both glia (astrocytes and
microglia) and neurons, the major cellular components of the
brain parenchyma (45). Although cyst formation primarily
occurs in neurons (46, 47), interactions between Toxoplasma
and glial cells play a crucial role during initial parasite
dissemination and reactivation (48–50), potential ly
contributing to the development of encephalitis. In this study,
Toxoplasma infection-induced changes in the mRNA levels of
complement components in the brain and glial cells were
examined, focusing on the alternative pathway and
anaphylatoxin C3a and C5a receptors, using in vivo and in
vitro infection models.METHODS
Reagents
Minocycline hydrochloride was purchased from FUJIFILM
Wako Pure Chemical Co. (Osaka, Japan). Sulfadiazine and
pyrimethamine were purchased from Tokyo Chemical Industry
Co., Ltd. (Tokyo, Japan).
Animals
C57BL/6J mice were purchased from Japan SLC (Shizuoka,
Japan). All animals were housed under specific pathogen-free
conditions at Chiba University Animal Facility. This study was
carried out according to protocols approved by the Ethics
Committee of Chiba University (permit number: A30-149).
Toxoplasma Infection In Vivo
Avirulent T. gondii Fukaya strain (type II) was used for in vivo
experiments. C57BL/6J mice (male, 5-week old) were orally
infected with three T. gondii Fukaya cysts using a syringe fitted
with a rounded needle. The brain homogenate of C57/B6J mice 6
weeks post-infection was used as a source of T. gondii Fukaya
cysts. Mock-infected (control) mice received 200 µL phosphate
buffered saline (PBS). Sulfadiazine (200 mg/kg per day) and
pyrimethamine (12.5 mg/kg per day) were suspended in water
containing 1% carboxymethyl cellulose and orally administered
using disposable, flexible feeding needles (Fuchigami Ltd., Kyoto,
Japan), from day 1 to day 14 after inoculation. Two or 8 weeks
after inoculation, mice were anesthetized with sodium
pentobarbital 80 mg/kg (i.p.), and then sacrificed by cervicalFrontiers in Immunology | www.frontiersin.org 3dislocation. Cerebral cortices were isolated in ice-cold PBS under
a stereoscopic microscope. The left and right cortices were used
for RNA isolation and DNA extraction, respectively.
Glial Cell Cultures
Cortical glial cells were prepared from postnatal days 1–2 mice
(C57BL/6J) as described previously (51). Briefly, cerebral cortices
were isolated in Hank’s Balanced Salt Solution, freed from
meninges, and mechanically dissociated using a 70 µm cell
strainer (BD Falcon, Durham, NC, USA). Cells were cultured
in Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma-
Aldrich, St Louis, MO, USA) supplemented with 10% (v/v)
fetal bovine serum (FBS; Life Technologies, Bleiswijk, the
Netherlands), 2 mM glutamine, and antibiotics (penicillin and
streptomycin) at 5% CO2 and 37°C. Cells were dissociated using
Accutase (Nacalai tesque, Inc. Kyoto, Japan) and re-plated in
DMEM containing 10% (v/v) FBS onto poly-D-lysine-coated
plates at a density of 20,000 cells/cm2. For immunofluorescence,
cells were seeded onto poly-D-lysine-coated glass coverslips at
the same density. Microglia-enriched culture was prepared by
replacing the medium at confluency with DMEM: Nutrient
Mixture F-12 (DMEM/F12; Life Technologies) supplemented
with 10% (v/v) FBS and antibiotics. Microglia-inactivated
cultures were prepared by pre-treatment with 20 µM
minocycline, a microglia inhibitor (52, 53), for 5 days prior to
use. Medium was replaced with DMEM/F12 containing 2% (v/v)
FBS for T. gondii infection.
Toxoplasma Infection In Vitro
T. gondii PTG-GFP strain (type II) (ATCC 50941, ATCC, VA,
USA) was amplified in Vero cells and tachyzoites were isolated
for in vitro assays as described previously (54). Isolated
tachyzoites were seeded onto glial cells at 10,000 tachyzoites/
cm2 in DMEM/F12 containing 2% (v/v) FBS, with or without
anti-Toxoplasma drug pyrimethamine (2 µM), and incubated for
48 h prior to DNA or RNA extraction.
Quantitative Real-Time PCR
RNA isolation was performed using RNAiso Plus (TAKARA
BIO INC., Shiga, Japan) according to the manufacturer’s
instruction. Reverse transcription was performed using
ReverTra Ace qPCR RT Master Mix with gDNA Remover
(TOYOBO Co., Osaka, Japan). Genomic DNA (gDNA)
isolation was performed using DNeasy Blood & Tissue Kits
(TAKARA) according to the manufacturer’s instruction.
Quan t i t a t i v e PCR (qPCR) was pe r f o rmed us ing
THUNDERBIRD SYBR qPCR Mix (TOYOBO Co.) and
StepOnePlus Real-Time PCR System (Thermo Fisher
Scientific). The temperature profile of real-time PCR was 95°C
for 60 s, followed by 40 cycles of 95°C for 10 s and 60°C for 30 s.
The following primer sequences were used according to
PrimerBank (https://pga.mgh.harvard.edu/primerbank/) (55):
mouse beta actin (GenBank Accession: NM_007393): Actb_fwd
GGCTGTATTCCCCTCCATCG, Actb_rev CCAGTTGGT
AACAATGCCATGT; mouse C3 (NM_009778): C3_fwd
CCAGCTCCCCATTAGCTCTG, C3_rev GCACTTGCCTC
TTTAGGAAGTC; mouse C3aR (NM_009779): C3ar1_fwdFebruary 2021 | Volume 11 | Article 603924
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TAGACAAGTGAGACCAA; mouse C5aR1 (NM_007577):
C5ar1_fwd CATACCTGCGGATGGCATTCA, C5ar1_rev
GGAACACCACCGAGTAGATGAT ; mou s e C1q a
(NM_007572): C1qa_fwd AAAGGCAATCCAGGCAATATCA,
C1qa_rev TGGTTCTGGTATGGACTCTCC; mouse
complement factor P (properdin) (NM_008823): Cfp_fwd
TTCACCCAGTATGAGGAGTCC, Cfp_rev GCTGACC
ATTGTGGAGACCT; mouse complement factor B (FB)
(NM_008198): Cfb_fwd GAGCGCAACTCCAGTGCTT,
Cfb_r ev GAGGGACATAGGTACTCCAGG; mouse
complement factor H (FH) (NM_009888): Cfh_fwd
AGGCTCGTGGTCAGAACAAC, Cfh_rev GTTAGA
CGCCACCCATTTTCC; C4b- binding protein (C4BP)
(NM_007576): C4bp_fwd ACAAGAGCTGCACATGGGAG,
C4bp_rev GGCATTGGGTATAGCAGGTGG. The following
primer sequences were used for gDNA quantification: mouse
beta actin: Actb_fwd TGTCTTGATAGTTCGCCATGGA,




C5a levels in the cerebral cortex were analyzed by ELISA. Isolated
tissues were homogenized in ice-cold RIPA buffer containing
protease inhibitor cocktail (Nacalai Tesque, Inc. Kyoto, Japan),
centrifuged at 4°C for 15 min, and the supernatants were
collected for assay. ELISA was performed using mouse
complement C5a ELISA kit according to manufacturer’s
instruction (abcam, Cambridge, UK).
Immunocytochemistry
Microglia-enriched culture with or without pre-treatment with
minocycline (20 µM) grown on the glass coverslips were fixed
with 4% (w/v) paraformaldehyde for 20 min at room
temperature. Cells were permeabilized and blocked using 0.1%
(v/v) Triton X-100 (TX100) and 5% (v/v) FBS in Tris-buffered
saline (TBS), and incubated overnight at 4°C with primary
antibodies: rabbit anti-Glial Fibrillary Acidic Protein (GFAP)
(1:1000, Agilent Technologies, Santa Clara, CA USA) and rat
anti-CD11b (1:1000, abcam, Cambridge, UK) in TBS containing
0.01% (v/v) TX100. The following secondary antibodies were
used: goat anti-rabbit Alexa Fluor 488 and goat anti-rat Alexa
Fluor 555, according to the manufacturer’s instructions (Thermo
Fisher). Nuclei were stained with DAPI (0.3 µM in TBS). Images
were captured using OLYMPUS IX71N-22PH fluorescence
microscope with filter sets: U-MWU2 (Ex: 330–385 nm/Em:
420 nm) for blue, U-MNIBA3 (Ex: 470–495 nm/Em 510–550
nm) for green, and U-MWIG3 (Ex: 530–550 nm/Em: 575 nm)
for red, equipped with Q Capture Pro 7.0 image analyzer (Media
Cybernetics, MD USA).
Statistical Analysis
Statistical analyses were performed using JMP Pro 13 (SAS
Institute Inc., Cary, NC USA). All data were expressed as the
mean ± SEM. P < 0.05 (by Student’s t test, Dunnett’s test, or
Tukey’s test) was considered statistically significant.Frontiers in Immunology | www.frontiersin.org 4RESULTS
Toxoplasma Infection Persistently
Increased the mRNA Levels of Alternative
Complement Pathway Components and
Anaphylatoxin Receptors
To determine whether the alternative complement pathway and
downstream anaphylatoxin signaling are also affected, mRNA
levels for complement components were measured 2 or 8 weeks
after oral inoculation. Toxoplasma infection induced a transient
reduction and gradual recovery of body weight during the first 2
weeks after inoculation (Figures 1A, B), consistent with the
previous findings showing that systemic parasite dissemination
and resolution occur during this period (56, 57). After the initial
dissemination, Toxoplasma establishes a chronic infection in the
brain, which was confirmed by the presence of Toxoplasma
gDNA in the brain cortex 2 weeks after inoculation (Figure
1C). In contrast, the weight gain of mice treated with the
combination of sulfadiazine and pyrimethamine, a standard
anti-Toxoplasma treatment, was comparable to that of control
without infection (Figure 1B), suggesting that the drug
treatment effectively suppressed parasite dissemination. The
effectiveness of the drug treatment was also confirmed by the
absence of Toxoplasma gDNA in the brain tissue of drug-treated
mice 2 weeks after infection (Figure 1C). Infection-induced
alterations in the mRNA expression levels of complement
components were assessed by qPCR (Figure 1D). Two weeks
after infection, C1q (C1qa) and C3 (C3) expression increased, as
suggested previously (42–44). In addition, Toxoplasma infection
induced a marked up-regulation of properdin (Cfp) and CFB
(Cfb), which was abrogated by anti-Toxoplasma drug treatment.
CFH (Cfh) expression was unaltered, suggesting enhancement
specifically of alternative complement pathway activity.
Curiously, Toxoplasma infection led to a decrease in C4BP
(C4bp), an inhibitor of the classical and lectin pathways;
however, this decrease was not attenuated by the drug
treatment. Furthermore, infection induced the expression of
C3aR (C3ar1) and C5aR1 (C5ar1). These results suggest that
Toxoplasma infection enhances alternative complement pathway
activ i ty as wel l as anaphylatoxin signal ing in the
brain parenchyma.
In order to assess whether the observed alterations are sustained,
the cortical mRNA levels of complement components were
measured 2 months after inoculation (Figures 2A–C). Cfp levels
did not differ between infected and control groups, suggesting that
infection-induced upregulation of properdin was transient (Figure
2D), and possibly associated with the acute phase of infection. On
the other hand, C1qa, C3, Cfb, C3ar1, andC5ar1 expression levels in
the cortex remained higher in the infected group compared to the
control group (Figure 2D), indicating that these factors are
persistently upregulated in the brain parenchyma during chronic
Toxoplasma infection. In addition, C5a protein levels were
significantly higher in the cerebral cortex of infected mice,
compared to non-infected control (Figure 3), supporting that
complement cascade is indeed activated, leading to the release of
cleavage products.February 2021 | Volume 11 | Article 603924
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Expression of Complement Components
in Glial Cells
In order to assess howToxoplasma infection affected the expression of
complement components in glial cells, mRNA levels of complement
components were determined by qPCR, using murine primary glial
cells exposed to Toxoplasma for 48 h (Figure 4). To address the
potential involvement of microglia-astrocyte crosstalk, infection-
induced responses were compared between mixed glial cultures,
containing both astrocytes and microglia, and cultures pre-treated
with minocycline, a microglia inhibitor, prior to infection, which
mainly consisted of astrocytes and had significantly fewer microglia
(Figure 4A). Cell culture without minocycline contained 19.6% of
microglia, whereas the percentage of microglia was less than 4.0%
after minocycline pre-treatment, according to cell counting (data not
shown). Basal expression levels of Cfp, C1qa, C3, C3ar1, and C5ar1
were significantly lower inminocycline pre-treated glia, whileCfb,Cfh
and C4bp levels were not affected (Figure 4B), suggesting that Cfp,
C1qa,C3,C3ar1, andC5ar1 are upregulated in amicroglia-dependent
manner, either in microglia themselves or in astrocytes dependent on
crosstalk with microglia. Toxoplasma infection increased mRNA
levels of Cfp, Cfb, C3, and C5ar1, which was observed only inFrontiers in Immunology | www.frontiersin.org 5mixed glial cultures without minocycline pre-treatment (Figure
4B). This upregulation was attenuated in the presence of the anti-
Toxoplasma drug pyrimethamine, confirming that the alterations in
the expression pattern were infection-dependent.DISCUSSION
The CNS has long been viewed as immunologically privileged.
However, it is now evident that glial cells and interactions thereof
play important immunological roles in the normal brain as well
as in disease (58). This study demonstrated that Toxoplasma
infection induced alteration in the expression patterns of
complement components in the brain and in glial cell cultures.
The observation that CFP, CFB, C3, and C5aR1 mRNAs were
induced in mixed glial cultures containing both astrocytes and
microglia, but not in the cells pre-treated with microglial
inhibitor minocycline, suggests that Toxoplasma infection
enhances alternative complement pathway activity and C5aR1
signaling via interactions with microglia. Of note, it has
been shown that Toxoplasma-infected microglia exhibited




FIGURE 1 | Toxoplasma infection induced the expression of alternative complement components and anaphylatoxin receptors in the brain. (A) Experimental
scheme. C57BL/6J mice were divided into three groups: without infection (n=3), T. gondii infection (n=6), and T. gondii infection plus drug treatment (Sulfadiazine
and pyrimethamine) (n=3). Infection groups received oral inoculation of T. gondii (Fukaya, three cysts) on day 0 at the age of 5 weeks, and one group received drug
treatment daily from day 1 for 2 weeks until sacrifice. (B) Body weight change after Toxoplasma inoculation. Data are presented as means ± SEM values relative to
body weight at day 0. Filled circle: without infection; filled square: infection; filled triangle: infected with drug treatment. (C) T. gondii gDNA levels were quantified by
qPCR. Values were normalized to mouse b-actin (Actb). Data are presented as Means ± SEM. (D) mRNA levels for complement components (properdin: Cfp, factor
B: Cfb, factor H: Cfh, C4b-binding protein: C4bp, C1q: C1qa, C3: C3, C3aR: C3ar1, and C5aR1: C5ar1) in the cortex. Data are presented as means ± SEM.
*p < 0.05, **p < 0.01 ***p < 0.001 (Dunnett’s test vs. control). The representative outcome of two independent experiments are presented.February 2021 | Volume 11 | Article 603924
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It is possible that the hypermotility of Toxoplasma-infected
microglia also contribute to the propagation of enhanced
complement activity in various brain regions. In addition,
while Toxoplasma infection induced the up-regulation of CFP,
CFB, C3, and C5aR1 mRNAs both in the brain and cultured glialFrontiers in Immunology | www.frontiersin.org 6cells, C1q and C3aR mRNAs increased only in the brain.
These observations suggest that Toxoplasma infection directly
induces the upregulation of CFP, CFB, C3, and C5aR1 in glial
cells whereas the induction of C1q and C3aR requires other
cellular components.
Microglia and astrocytes are the major glial populations that
regulate homeostasis in the normal brain, and microglia-astrocyte
crosstalk determines their functionality (60). Microglia are brain-
resident immune cells, monitoring and responding to damage-
associated microenvironmental cues and clearing cellular debris
(61). In addition, microglia play key roles in synaptic formation,
sculpting, and myelination during prenatal and postnatal brain
development (62), and directly monitor the functional state of
neurons and synaptic activities, and regulate synaptic plasticity in
the intact brain throughout the entire lifespan (63). While these cells
are essential part of the CNS, their dysfunction and overactivation
can lead to neuroinflammation leading to various brain
dysfunctions (64, 65). Glial activation has been discussed most
frequently in association with increased production of inflammatory
cytokines and chemokines (66). Meanwhile, growing evidence
suggests significant roles of complement components in
microglia-mediated neuropathological events (67–69). Microglia




FIGURE 2 | mRNAs for factor B and anaphylatoxin receptors are persistently upregulated after Toxoplasma infection. (A) C57BL/6J were divided into two groups:
with (n=4) or without infection (n=4). The infection group received oral inoculation of T. gondii (Fukaya, three cysts) at the age of 5 weeks. (B) Body weight was
measured before inoculation and from week 6 to week 8 until sacrifice. Body weight change from week 6 to week 8. Data are presented as means ± SEM. (C) T.
gondii gDNA levels were quantified by qPCR. Values were normalized to mouse b-actin (Actb). Data are presented as means ± SEM. (D) mRNA levels for
complement components (properdin: Cfp, factor B: Cfb, factor H: Cfh, C4b-binding protein: C4bp, C1q: C1qa, C3: C3, C3aR: C3ar1, and C5aR1: C5ar1) in the
cortex. Data are presented as means ± SEM. ***p < 0.001 (Student’s t-test vs. control). The representative outcome of two independent experiments are presented.FIGURE 3 | C5a increased in the cerebral cortex after Toxoplasma infection.
One month after infection, C5a protein levels in the cortical tissue lysates
were measured by ELISA. Data are normalized by total protein and presented
as means ± SEM (n=4). **p < 0.01 (Student’s t-test vs. control). The
representative outcome of two independent experiments are presented.February 2021 | Volume 11 | Article 603924
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microglial population is established in the early postnatal period
(70). Importantly, during the postnatal period, microglia-mediated
synaptic elimination and remodeling occur in a complement-
dependent manner (71), suggesting that altered microglial
complement activity during this period could have detrimental
consequences in CNS development. Congenital toxoplasmosis is
frequently associated with neurodevelopmental disorders, such as
psychomotor retardation, intellectual disability, epilepsy, and autism
spectrum disorders (72). In addition, later in life, Toxoplasma
infection is related to a number of neuropsychiatric disorders,
including anxiety, depression, and schizophrenia (72), which are
associated with altered glial activity and neuroplasticity (35, 73).
Thus, Toxoplasma-microglia interaction and infection-induced
changes in complement activity could underlie detriments to
CNS development and maturation. This study showed that
Toxoplasma infection upregulated CFP and CFB mRNAs in the
brain via direct interaction with microglial cells. Activation of the
alternative complement pathway has been implicated in various
brain disorders, including prion infection (25), suggesting
potential contribution of alternative complement pathway
activation to the development of cerebral toxoplasmosis. The
current study also demonstrated that Toxoplasma infection
caused sustained upregulation of C5aR1 and C3aR mRNAs in
the brain. C5aR1 is primarily expressed onmyeloid cells, includingFrontiers in Immunology | www.frontiersin.org 7microglia (74), and C5aR1 signaling is involved in brain
dysfunctions associated with neuroinflammation, such as
epilepsy (75) and neurodegenerative disorders (76). Inhibition of
C3aR or C5aR1 is frequently associated with neuroprotection
against injuries, such as stroke (77–79). Furthermore, murine
experimental malaria in pregnancy induced neurocognitive
deficits in the offspring via C5aR1 signaling, which were
independent of in utero parasite transfer (24). These data
suggest that damage-associated C5aR1 signaling could potentiate
neuroinflammation, possibly exacerbating defects in neural
development and repair processes. On the other hand, neuronal
populations also express complement components (13), and C3aR
and C5aR1 are required for neuronal migration during cortical
development (13, 17). In addition, C3aR signaling activation
enhances neural plasticity after ischemic injury (80), suggesting
the roles of C3aR in the protection and repair of the CNS
depending on the context. Thus, it is possible that sustained
upregulation of C3aR and C5aR1 in the brain after Toxoplasma
infection is part of the defense against infection-induced damages
in the CNS. Similarly, C1q-dependent microglial phagocytosis
may be associated with debris-clearance (81) and synaptic
reorganization (82), as part of the recovery processes. The
significance of neuronal complement activation in the context of
Toxoplasma infection is another future research direction. Of note,
T. gondii is classified into virulent (type I) and avirulent (type IIA B
FIGURE 4 | Toxoplasma infection induced the upregulation of alternative complement pathway components and anaphylatoxin C5aR1. (A) Primary mixed glial cells
prepared from the cortex of postnatal days 1–2 C57BL/6J mice. Astrocytes and microglia were detected by immunofluorescence microscopy, using Glial Fibrillary
Acidic Protein (GFAP, green) and CD11b (red) as marker proteins. Cultures were pre-treated either in the presence or absence of minocycline (20 µM) for 5 days
prior to T. gondii infection (upper panel). Without minocycline pre-treatment, glial culture contained significantly more CD11b positive microglia (lower panel).
(B) mRNA levels of complement components (Cfp, Cfb, Cfh, C4bp, C1qa, C3, C3ar1, and C5ar1) in glial cells with or without T. gondii infection in the presence or
absence of anti-Toxoplasma drug pyrimethamine (2 µM). Means ± SEM. *p < 0.05, **p < 0.01 ***p < 0.001 (Tukey’s test).February 2021 | Volume 11 | Article 603924
Shinjyo et al. Complement Activation in CNS Infectionand type III) strains. While avirulent T. gondii forms tissue cysts,
causing long-lasting infection in the brain, virulent T. gondii
exhibits significantly lower cyst-forming potential (83). It
remains to be elucidated whether the complement system
responds to Toxoplasma infection differently depending on
the virulence.
This study demonstrated that Toxoplasma infection induced
upregulation of alternative complement components and
anaphylatoxin receptors, in part mediated via Toxoplasma-microglia
interaction. The exact nature and significance of the observed
phenomenon are unknown; however, it is plausible that infection-
induced modulation of complement activity has either detrimental or
beneficial effects, determining the fate of cerebral toxoplasmosis.
Further research is warranted to evaluate the functional significance.DATA AVAILABILITY STATEMENT
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